Related Experiment Video
Updated: Jun 20, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.3K
Balancing the risks: continuous vs. interrupted anticoagulation during TAVI - what does the evidence say?
Ravi Patel1, Emmanuel Kokori2, Gbolahan Olatunji3
1Methodist Health System Dallas, Dallas, TX, USA.
Thrombosis Journal
|January 24, 2025
Summary
Continuous anticoagulation may reduce mortality and stroke after transcatheter aortic valve implantation (TAVI). However, risks of bleeding and inconsistent findings necessitate individualized patient strategies for optimal outcomes.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Anticoagulation is crucial after transcatheter aortic valve implantation (TAVI) to prevent thromboembolic events.
- Managing anticoagulation post-TAVI involves balancing efficacy and bleeding risks.
Purpose of the Study:
- To review and compare continuous versus interrupted anticoagulation strategies in TAVI patients.
- To assess the impact of different anticoagulation regimens on mortality, stroke, and composite events.
Main Methods:
- A literature review of recent studies evaluating anticoagulation in TAVI patients.
- Analysis of clinical outcomes including all-cause mortality, thromboembolic events, and cardiovascular complications.
Main Results:
- A trend suggests continuous anticoagulation, especially with direct-acting oral anticoagulants (DOACs), may lower mortality and stroke in high-risk TAVI patients.
- Study findings on continuous versus interrupted strategies were inconsistent.
- Continuous therapy increases bleeding and vascular complication risks.
Conclusions:
- Individualized anticoagulation strategies are essential for TAVI patients, tailored to their specific risk profiles.
- Clinicians must carefully weigh the benefits of continuous anticoagulation against its associated risks.
- Further research is needed to optimize anticoagulation protocols for TAVI patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...